Table 1.
Baseline characteristics
| Characteristic | Full cohort N = 20 |
ADC exposed∗ n = 13 |
Bispecific exposed∗ n = 7 |
|---|---|---|---|
| Median age (range), years | 62.5 (44-81) | 66.0 (44-81) | 60.0 (49-71) |
| Male | 12 (60.0) | 8 (61.5) | 4 (57.1) |
| Race | |||
| White | 19 (95.0) | 13 (100) | 6 (85.7) |
| Black | 1 (5.0) | 0 | 1 (14.3) |
| Baseline ECOG score† | |||
| 0 | 8 (40.0) | 3 (23.1) | 5 (71.4) |
| 1 | 12 (60.0) | 10 (76.9) | 2 (28.6) |
| Time from initial MM diagnosis, median (range) years | 6.3 (2.5-16.3) | 6.4 (3.6-16.3) | 5.0 (2.5-14.5) |
| ISS stage (at study entry) | |||
| I | 8 (40.0) | 6 (46.2) | 2 (28.6) |
| II | 4 (20.0) | 3 (23.1) | 1 (14.3) |
| III | 8 (40.0) | 4 (30.8) | 4 (57.1) |
| Plasmacytoma‡ | 5 (25.0) | 5 (38.5) | 0 |
| Bone marrow plasma cells ≥60%§ | 6 (31.6) | 4 (33.3) | 2 (28.6) |
| Type of measurable disease | |||
| Serum only | 5 (25.0) | 4 (30.8) | 1 (14.3) |
| Serum and urine | 4 (20.0) | 2 (15.4) | 2 (28.6) |
| Urine only | 5 (25.0) | 2 (15.4) | 3 (42.9) |
| Serum free light chain | 5 (25.0) | 4 (30.8) | 1 (14.3) |
| Not evaluable‖ | 1 (5.0) | 1 (7.7) | 0 |
| Cytogenetic profile | |||
| Standard risk | 9 (45.0) | 6 (46.2) | 3 (42.9) |
| High risk (all del17p)¶ | 3 (15.0) | 2 (15.4) | 1 (14.3) |
| Unknown | 8 (40.0) | 5 (38.5) | 3 (42.9) |
| Number of prior lines of therapy, median (range) | 8 (4-13) | 8 (4-13) | 8 (6-12) |
| Previous stem cell transplant | |||
| Autologous | 20 (100.0) | 13 (100.0) | 7 (100.0) |
| Allogeneic | 2 (10.0) | 0 | 2 (28.6) |
| Prior exposure | |||
| Noncellular anti-BCMA | 20 (100.0) | 13 (100.0) | 7 (100.0) |
| Anti-BCMA bispecific Ab | 8 (40.0) | 1 (7.7) | 7 (100.0) |
| Teclistamab | 3 (15.0) | 0 | 3 (42.9) |
| AMG 420 | 1 (5.0) | 0 | 1 (14.3) |
| AMG 701 | 1 (5.0) | 0 | 1 (14.3) |
| PF-06863135 | 1 (5.0) | 0 | 1 (14.3) |
| WVT078 | 1 (5.0) | 0 | 1 (14.3) |
| REG5459# | 1 (5.0) | 1 (7.7) | 0 |
| Anti-BCMA ADC | 13 (65.0) | 13 (100.0) | 0 |
| Belantamab mafodotin | 13 (65.0) | 13 (100.0) | 0 |
| MEDI2228# | 1 (5.0) | 1 (7.7) | 0 |
| Therapy in last line | |||
| Anti-BCMA | 6 (30.0) | 4 (30.8) | 2 (28.6) |
| Other treatments | 14 (70.0) | 9 (69.2) | 5 (71.4) |
| Refractory to last line of prior therapy | 19 (95.0) | 13 (100.0) | 6 (85.7) |
| Triple-class refractory∗∗ | 18 (90.0) | 11 (84.6) | 7 (100.0) |
| Penta-drug refractory†† | 11 (55.0) | 7 (53.8) | 4 (57.1) |
| Anti-BCMA treatment refractory | 16 (80.0) | 11 (84.6) | 5 (71.4) |
Data are n (%) except where otherwise specified.
ADC, antibody-drug conjugates; BCMA, B-cell maturation antigen; ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System; MM, multiple myeloma.
Classification is based on the last anti-BCMA therapy used if patients received >1 therapy.
The last nonmissing European Cooperative Oncology Group score before cilta-cel infusion was used.
All were extramedullary.
Maximum value from bone marrow biopsy and bone marrow aspirate is selected if both results are available.
Patients with neither serum nor urine measurable disease who had extramedullary lesions could be using positron-emission/computed tomography or whole-body magnetic resonance imaging to satisfy the measurable disease criteria per protocol.
High-risk category defined as del17p, t(4,14), or t(14,16).
REG5459 and MEDI2228 were administered before belantamab, which was the last anti-BCMA therapy for all ADC-exposed patients.
At least 1 proteasome inhibitor, ≥1 immunomodulatory drug, and 1 anti-CD38 antibody.
At least 2 proteasome inhibitors, ≥2 immunomodulatory drugs, and 1 anti-CD38 antibody.